(IN BRIEF) Novartis will present 19 abstracts at the 2025 European Society of Cardiology (ESC) Congress in Madrid, showcasing new findings across its cardiovascular portfolio. Key highlights include two VictORION studies on Leqvio’s impact on quality of life and its … Read the full press release →
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged abelacimab, atrial fibrillation, AZALEA-TIMI 71, cardiovascular disease, cardiovascular pipeline therapies, Chagas disease, Entresto, ESC Congress 2025, European Society of Cardiology, heart failure, inclisiran, Leqvio, lipoprotein apheresis, lipoprotein(a), Lp(a)FRONTIERS APHERESIS trial, Novartis, PARACHUTE-HF trial, pelacarsen, Sacubitril Valsartan, VictORION studies, xRNA platform